In this month’s Catabasis Connection, they discuss: Learning in their Phase 3 PolarisDMD trial Boys with Duchenne demonstrate capsule swallowing abilities The expected patient population Safety data on edasalonexent.
Newport Beach, CA, May 7, 2020 – CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, is announcing the Virtual Napa Wine Series […]
— The Interim data from EPYDIS Phase 3 trial shows that the trial is NOT FUTILE and the Independent Data Monitoring Committee recommends trial continuation — — Blinded re-estimation of […]
Newport Beach, CA & Seattle, WA, April 22, 2020: Myosana Therapeutics, Inc., a new biotech company developing novel platform technology for non-viral gene delivery, raised up to $1M in seed […]
CureDuchenne Ventures is happy to announce its latest investment in Myosana Therapeutics, a new biotech company based in Seattle, WA. Myosana is aiming to develop next-generation gene therapy for Duchenne muscular dystrophy and other neuromuscular […]
Dear Duchenne Community, I’m truly thrilled about our investment in a new biotech company called Myosana Therapeutics. Myosana aims to develop next-generation gene therapy for Duchenne muscular dystrophy and neuromuscular diseases. Because of this investment, the team is now positioned to conduct […]
Dear Duchenne Community, We are proud that, through these difficult times, CureDuchenne is continuing to invest in research, to expand our programs and offer services to the Duchenne Community. All of us are feeling the personal, emotional and financial toll […]
